154 related articles for article (PubMed ID: 33792041)
1. Generation and characterization of a high-affinity chimeric anti-OX40 antibody with potent antitumor activity.
Yang Y; Chai X; Xin W; Wang D; Dai C; Qian F; Yang T
FEBS Lett; 2021 Jun; 595(11):1587-1603. PubMed ID: 33792041
[TBL] [Abstract][Full Text] [Related]
2. Fc Engineering Approaches to Enhance the Agonism and Effector Functions of an Anti-OX40 Antibody.
Zhang D; Goldberg MV; Chiu ML
J Biol Chem; 2016 Dec; 291(53):27134-27146. PubMed ID: 27856634
[TBL] [Abstract][Full Text] [Related]
3. Bifunctional macromolecule activating both OX40 and interferon-α signaling displays potent therapeutic effects in mouse HBV and tumor models.
Mo S; Gu L; Xu W; Liu J; Ding D; Wang Z; Yang J; Kong L; Zhao Y
Int Immunopharmacol; 2020 Dec; 89(Pt B):107099. PubMed ID: 33091819
[TBL] [Abstract][Full Text] [Related]
4. OX40 is a potent immune-stimulating target in late-stage cancer patients.
Curti BD; Kovacsovics-Bankowski M; Morris N; Walker E; Chisholm L; Floyd K; Walker J; Gonzalez I; Meeuwsen T; Fox BA; Moudgil T; Miller W; Haley D; Coffey T; Fisher B; Delanty-Miller L; Rymarchyk N; Kelly T; Crocenzi T; Bernstein E; Sanborn R; Urba WJ; Weinberg AD
Cancer Res; 2013 Dec; 73(24):7189-7198. PubMed ID: 24177180
[TBL] [Abstract][Full Text] [Related]
5. Science gone translational: the OX40 agonist story.
Weinberg AD; Morris NP; Kovacsovics-Bankowski M; Urba WJ; Curti BD
Immunol Rev; 2011 Nov; 244(1):218-31. PubMed ID: 22017441
[TBL] [Abstract][Full Text] [Related]
6. Preparation and characterization of a high-affinity monoclonal antibody against nerve growth factor.
Liu S; Shen Y; Chen P; Guo C; Zhang G; Jiang X; He J; Yang J
Protein Expr Purif; 2022 Jan; 189():105966. PubMed ID: 34627999
[TBL] [Abstract][Full Text] [Related]
7. Ligand-Blocking and Membrane-Proximal Domain Targeting Anti-OX40 Antibodies Mediate Potent T Cell-Stimulatory and Anti-Tumor Activity.
Zhang P; Tu GH; Wei J; Santiago P; Larrabee LR; Liao-Chan S; Mistry T; Chu ML; Sai T; Lindquist K; Long H; Chaparro-Riggers J; Salek-Ardakani S; Yeung YA
Cell Rep; 2019 Jun; 27(11):3117-3123.e5. PubMed ID: 31189099
[TBL] [Abstract][Full Text] [Related]
8. Timing of PD-1 Blockade Is Critical to Effective Combination Immunotherapy with Anti-OX40.
Messenheimer DJ; Jensen SM; Afentoulis ME; Wegmann KW; Feng Z; Friedman DJ; Gough MJ; Urba WJ; Fox BA
Clin Cancer Res; 2017 Oct; 23(20):6165-6177. PubMed ID: 28855348
[No Abstract] [Full Text] [Related]
9. Obtaining and characterization of monoclonal antibodies against recombinant extracellular domain of human epidermal growth factor receptor 2.
Sarina N; Abeldenov S; Turgimbayeva A; Zhylkibayev A; Ramankulov Y; Khassenov B; Eskendirova S
Hum Antibodies; 2018 Feb; 26(2):103-111. PubMed ID: 29036807
[TBL] [Abstract][Full Text] [Related]
10. Roscovitine suppresses CD4+ T cells and T cell-mediated experimental uveitis.
Zhang Z; Liu Q; Leskov KS; Wu X; Duan J; Zhang GL; Hall M; Rosenbaum JT
PLoS One; 2013; 8(11):e81154. PubMed ID: 24260551
[TBL] [Abstract][Full Text] [Related]
11. Potent Immune Modulation by MEDI6383, an Engineered Human OX40 Ligand IgG4P Fc Fusion Protein.
Oberst MD; Augé C; Morris C; Kentner S; Mulgrew K; McGlinchey K; Hair J; Hanabuchi S; Du Q; Damschroder M; Feng H; Eck S; Buss N; de Haan L; Pierce AJ; Park H; Sylwester A; Axthelm MK; Picker L; Morris NP; Weinberg A; Hammond SA
Mol Cancer Ther; 2018 May; 17(5):1024-1038. PubMed ID: 29545330
[TBL] [Abstract][Full Text] [Related]
12. Monoclonal Antibody Against Human GLRX3.
Monoclon Antib Immunodiagn Immunother; 2016 Dec; 35(6):309. PubMed ID: 28029331
[No Abstract] [Full Text] [Related]
13. Ox40 costimulation enhances the development of T cell responses induced by dendritic cells in vivo.
De Smedt T; Smith J; Baum P; Fanslow W; Butz E; Maliszewski C
J Immunol; 2002 Jan; 168(2):661-70. PubMed ID: 11777959
[TBL] [Abstract][Full Text] [Related]
14. Anti-OX40 (CD134) administration to nonhuman primates: immunostimulatory effects and toxicokinetic study.
Weinberg AD; Thalhofer C; Morris N; Walker JM; Seiss D; Wong S; Axthelm MK; Picker LJ; Urba WJ
J Immunother; 2006; 29(6):575-85. PubMed ID: 17063120
[TBL] [Abstract][Full Text] [Related]
15. Characterization of rat OX40 ligand by monoclonal antibody.
Satake Y; Akiba H; Takeda K; Atsuta M; Yagita H; Okumura K
Biochem Biophys Res Commun; 2000 Apr; 270(3):1041-8. PubMed ID: 10772947
[TBL] [Abstract][Full Text] [Related]
16. CD137/OX40 Bispecific Antibody Induces Potent Antitumor Activity that Is Dependent on Target Coengagement.
Gaspar M; Pravin J; Rodrigues L; Uhlenbroich S; Everett KL; Wollerton F; Morrow M; Tuna M; Brewis N
Cancer Immunol Res; 2020 Jun; 8(6):781-793. PubMed ID: 32273279
[TBL] [Abstract][Full Text] [Related]
17. The CTLA-4 x OX40 bispecific antibody ATOR-1015 induces anti-tumor effects through tumor-directed immune activation.
Kvarnhammar AM; Veitonmäki N; Hägerbrand K; Dahlman A; Smith KE; Fritzell S; von Schantz L; Thagesson M; Werchau D; Smedenfors K; Johansson M; Rosén A; Åberg I; Winnerstam M; Nyblom E; Barchan K; Furebring C; Norlén P; Ellmark P
J Immunother Cancer; 2019 Apr; 7(1):103. PubMed ID: 30975201
[TBL] [Abstract][Full Text] [Related]
18. FcγRII-binding Centyrins mediate agonism and antibody-dependent cellular phagocytosis when fused to an anti-OX40 antibody.
Zhang D; Whitaker B; Derebe MG; Chiu ML
MAbs; 2018 Apr; 10(3):463-475. PubMed ID: 29359992
[TBL] [Abstract][Full Text] [Related]
19. Delivery of immunostimulatory monoclonal antibodies by encapsulated hybridoma cells.
Dubrot J; Portero A; Orive G; Hernández RM; Palazón A; Rouzaut A; Perez-Gracia JL; Hervás-Stubbs S; Pedraz JL; Melero I
Cancer Immunol Immunother; 2010 Nov; 59(11):1621-31. PubMed ID: 20607237
[TBL] [Abstract][Full Text] [Related]
20. Development and characterization of a novel anti-OX40 antibody for potent immune activation.
Kuang Z; Jing H; Wu Z; Wang J; Li Y; Ni H; Zhang P; Wu W; Wu M; Zhou S; Qiu X; Wu D; Prinz B; Baruah H; Chen B; Yu M; Liu J
Cancer Immunol Immunother; 2020 Jun; 69(6):939-950. PubMed ID: 32078015
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]